The exploratory basket study sponsored by West China Hospital aims to evaluate the safety and efficacy of a therapeutic mRNA vaccine targeting FAP in combination with immune checkpoint inhibitors for patients with advanced malignant solid tumors. Given the increasing interest in mRNA-based therapies and the critical role of CAFs in tumor progression, this trial could position the sponsor favorably within the oncology market. The potential to enhance the efficacy of existing immunotherapies by targeting the tumor microenvironment may provide a competitive edge against other therapies that do not address CAFs. However, the trial is not yet recruiting, and the timeline for results will be crucial for market positioning and investor interest.